OPTN Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -1.61% compared to OptiNose's net margin of -14.12%. OptiNose's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

OptiNose has a consensus price target of $18.00, signalling upside risk potential of 97.8%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $314.48 which suggests that it could grow by 33.4%. Given that OptiNose has higher upside potential than Alnylam Pharmaceuticals, analysts believe OptiNose is more attractive than Alnylam Pharmaceuticals.

OptiNose has a beta of -0.873, which suggesting that the stock is 187.316% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $22.4M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. OptiNose's net income of -$360K is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, OptiNose's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.19x versus 13.38x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Autonomix Medical has a net margin of -1.61% compared to OptiNose's net margin of --. OptiNose's return on equity of -- beat Autonomix Medical's return on equity of --.

OptiNose has a consensus price target of $18.00, signalling upside risk potential of 97.8%. On the other hand Autonomix Medical has an analysts' consensus of $18.00 which suggests that it could grow by 994.23%. Given that Autonomix Medical has higher upside potential than OptiNose, analysts believe Autonomix Medical is more attractive than OptiNose.

OptiNose has a beta of -0.873, which suggesting that the stock is 187.316% less volatile than S&P 500. In comparison Autonomix Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autonomix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Autonomix Medical pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $22.4M, which are larger than Autonomix Medical quarterly revenues of --. OptiNose's net income of -$360K is higher than Autonomix Medical's net income of -$2.7M. Notably, OptiNose's price-to-earnings ratio is -- while Autonomix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.19x versus -- for Autonomix Medical. Usually stocks with elevated PS ratios are considered overvalued.

Aptevo Therapeutics has a net margin of -1.61% compared to OptiNose's net margin of --. OptiNose's return on equity of -- beat Aptevo Therapeutics's return on equity of --.

OptiNose has a consensus price target of $18.00, signalling upside risk potential of 97.8%. On the other hand Aptevo Therapeutics has an analysts' consensus of $21.00 which suggests that it could grow by 1309.4%. Given that Aptevo Therapeutics has higher upside potential than OptiNose, analysts believe Aptevo Therapeutics is more attractive than OptiNose.

OptiNose has a beta of -0.873, which suggesting that the stock is 187.316% less volatile than S&P 500. In comparison Aptevo Therapeutics has a beta of 5.753, suggesting its more volatile than the S&P 500 by 475.252%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aptevo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Aptevo Therapeutics pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $22.4M, which are larger than Aptevo Therapeutics quarterly revenues of --. OptiNose's net income of -$360K is higher than Aptevo Therapeutics's net income of -$6.3M. Notably, OptiNose's price-to-earnings ratio is -- while Aptevo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.19x versus 0.05x for Aptevo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -1.61% compared to OptiNose's net margin of --. OptiNose's return on equity of -- beat Cassava Sciences's return on equity of --.

OptiNose has a consensus price target of $18.00, signalling upside risk potential of 97.8%. On the other hand Cassava Sciences has an analysts' consensus of $2.00 which suggests that it could grow by 53.85%. Given that OptiNose has higher upside potential than Cassava Sciences, analysts believe OptiNose is more attractive than Cassava Sciences.

OptiNose has a beta of -0.873, which suggesting that the stock is 187.316% less volatile than S&P 500. In comparison Cassava Sciences has a beta of -1.481, suggesting its less volatile than the S&P 500 by 248.1%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $22.4M, which are larger than Cassava Sciences quarterly revenues of --. OptiNose's net income of -$360K is higher than Cassava Sciences's net income of -$27.6M. Notably, OptiNose's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.19x versus 1.47x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.